Stifel Upgrades Silk Road Medical to Buy, Raises Price Target to $20
Stifel Upgrades Silk Road Medical to Buy, Raises Price Target to $20
Stifel將絲路醫療上調爲收購,將目標股價上調至20美元
Stifel analyst Rick Wise upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and raises the price target from $9 to $20.
Stifel分析師裏克·懷斯將絲路醫療(納斯達克股票代碼:SILK)從 “持有” 上調至 “買入”,並將目標股價從9美元上調至20美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。